Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Immune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor treatment by inducing immunogenic changes in the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniel Baumann, Tanja Hägele, Julian Mochayedi, Jennifer Drebant, Caroline Vent, Sven Blobner, Julia Han Noll, Irena Nickel, Corinna Schumacher, Sophie Luise Boos, Aline Sophie Daniel, Susann Wendler, Michael Volkmar, Oliver Strobel, Rienk Offringa
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/82d30f0ec62647d88279190f5c3cf28a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:82d30f0ec62647d88279190f5c3cf28a
record_format	dspace
spelling	oai:doaj.org-article:82d30f0ec62647d88279190f5c3cf28a2021-12-02T14:41:24ZProimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy10.1038/s41467-020-15979-22041-1723https://doaj.org/article/82d30f0ec62647d88279190f5c3cf28a2020-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-15979-2https://doaj.org/toc/2041-1723Immune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor treatment by inducing immunogenic changes in the tumor microenvironment.Daniel BaumannTanja HägeleJulian MochayediJennifer DrebantCaroline VentSven BlobnerJulia Han NollIrena NickelCorinna SchumacherSophie Luise BoosAline Sophie DanielSusann WendlerMichael VolkmarOliver StrobelRienk OffringaNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Daniel Baumann Tanja Hägele Julian Mochayedi Jennifer Drebant Caroline Vent Sven Blobner Julia Han Noll Irena Nickel Corinna Schumacher Sophie Luise Boos Aline Sophie Daniel Susann Wendler Michael Volkmar Oliver Strobel Rienk Offringa Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
description	Immune checkpoint inhibitors have limited efficacy in tumors with lower mutational burden and non-permissive microenvironment. Here, the authors show that combining MEK inhibition with an agonist anti-CD40 immunostimulatory antibody improves antitumor treatment by inducing immunogenic changes in the tumor microenvironment.
format	article
author	Daniel Baumann Tanja Hägele Julian Mochayedi Jennifer Drebant Caroline Vent Sven Blobner Julia Han Noll Irena Nickel Corinna Schumacher Sophie Luise Boos Aline Sophie Daniel Susann Wendler Michael Volkmar Oliver Strobel Rienk Offringa
author_facet	Daniel Baumann Tanja Hägele Julian Mochayedi Jennifer Drebant Caroline Vent Sven Blobner Julia Han Noll Irena Nickel Corinna Schumacher Sophie Luise Boos Aline Sophie Daniel Susann Wendler Michael Volkmar Oliver Strobel Rienk Offringa
author_sort	Daniel Baumann
title	Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_short	Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_full	Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_fullStr	Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_full_unstemmed	Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
title_sort	proimmunogenic impact of mek inhibition synergizes with agonist anti-cd40 immunostimulatory antibodies in tumor therapy
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/82d30f0ec62647d88279190f5c3cf28a
work_keys_str_mv	AT danielbaumann proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT tanjahagele proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT julianmochayedi proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT jenniferdrebant proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT carolinevent proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT svenblobner proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT juliahannoll proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT irenanickel proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT corinnaschumacher proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT sophieluiseboos proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT alinesophiedaniel proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT susannwendler proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT michaelvolkmar proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT oliverstrobel proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy AT rienkoffringa proimmunogenicimpactofmekinhibitionsynergizeswithagonistanticd40immunostimulatoryantibodiesintumortherapy
_version_	1718389880237588480

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Ejemplares similares